Shengnuo Bio: It is expected that the net profit will increase by 204.42% to 280.53% year-on-year in 2025.

Saint Nora Biotechnology announces that it is expected to achieve a net profit attributable to the owners of the parent company of 152 million to 190 million yuan in the fiscal year 2025, an increase of 102 million to 140 million yuan compared to the same period last year, a year-on-year increase of 204.42% to 280.53%; it is expected to achieve a net profit attributable to the owners of the parent company after deducting non-recurring gains and losses of 149 million to 186 million yuan in the fiscal year 2025, an increase of 103 million to 140 million yuan compared to the same period last year, a year-on-year increase of 226.07% to 307.58%. During the reporting period, the company closely focused on the annual operating strategy, promoted the landing of production capacity under construction, continued to expand domestic and international markets, resulting in continuous growth in orders for the company's peptide raw material pharmaceutical business, driving overall performance steadily improving, achieving a significant increase in performance compared to the same period last year, further enhancing the company's global competitiveness in the peptide pharmaceutical market.